moclobemide has been researched along with Cognition Disorders in 6 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The new reversible MAOl moclobemide was compared with placebo in the treatment of elderly patients with DSM-III diagnosis of dementia and/or of major depression." | 5.08 | Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. ( Amrein, R; Mountjoy, CQ; Roth, M, 1996) |
| " While clinical aspects will be presented in a subsequent review, this article focuses primarily on moclobemide's evolution, pharmacodynamic and pharmacokinetic properties." | 2.41 | Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties. ( Bonnet, U, 2002) |
| "Depression is a highly prevalent concomitant of dementia." | 2.40 | Depression and dementia: comorbidities, identification, and treatment. ( Meyers, BS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonnet, U | 1 |
| Galderisi, S | 1 |
| Mucci, A | 1 |
| Bucci, P | 1 |
| Mignone, ML | 1 |
| Maj, M | 1 |
| Roth, M | 1 |
| Mountjoy, CQ | 1 |
| Amrein, R | 2 |
| Meyers, BS | 1 |
| Martin, JR | 1 |
| Cameron, AM | 1 |
| Anand, R | 1 |
| Wesnes, KA | 1 |
3 reviews available for moclobemide and Cognition Disorders
| Article | Year |
|---|---|
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
Topics: Animals; Antidepressive Agents; Anxiety; Cognition Disorders; Depression; Disease Models, Animal; Dr | 2002 |
Depression and dementia: comorbidities, identification, and treatment.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Benzamides; Citalopram; Clomipramine; Cog | 1998 |
Moclobemide in patients with dementia and depression.
Topics: Animals; Benzamides; Cognition Disorders; Dementia; Depression; Humans; Moclobemide; Monoamine Oxida | 1999 |
1 trial available for moclobemide and Cognition Disorders
| Article | Year |
|---|---|
Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Benzamides; Cognition Disorders; Comorbidity; Dement | 1996 |
2 other studies available for moclobemide and Cognition Disorders
| Article | Year |
|---|---|
Influence of moclobemide on cognitive functions of nine depressed patients: pilot trial with neurophysiological and neuropsychological indices.
Topics: Adult; Antidepressive Agents; Arousal; Attention; Benzamides; Cognition Disorders; Depressive Disord | 1996 |
Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans.
Topics: Benzamides; Cognition Disorders; Double-Blind Method; Humans; Moclobemide; Monoamine Oxidase Inhibit | 1990 |